IMRT Tomotherapy for Esophagus Cancer



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:December 2006
End Date:December 2015

Use our guide to learn which trials are right for you!

IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients

Concurrent chemotherapy and radiation therapy are the standard of care for inoperable
patients with esophagus cancer. Unfortunately, the 5-year survival of 20% for this
population is quite low. Methods to intensify radiation therapy delivery without increasing
local toxicities are needed. Intensity modulated radiation therapy (IMRT) is an advanced
method of delivering external beam radiation that may minimize the volume of normal tissue
irradiated to high dose and thus decrease the risk of normal tissue toxicity. The proposed
study will prospectively test whether IMRT is tolerable for delivering IMRT doses of 60 Gy
for patients with esophagus cancer.


Inclusion Criteria:

- Age >= 18

- Karnofsky Performance Status of >= 60

- TNM Stages T1-4, N0-3, M0

- Pathologic confirmation of esophagus cancer

- Evaluation by medical oncologist determines that the patient is medically fit for
concurrent chemotherapy

- Evaluation by surgeon determines that patient is unresectable

Exclusion Criteria:

- Age < 18

- Karnofsky Performance Status < 60

- Radiographic or pathologic evidence of distant metastatic disease (classified as M1b
in AJCC staging manual)

- Prior radiation therapy to the thorax or upper abdomen, preventing definitive
radiation therapy.

- Pregnant or lactating, if female.
We found this trial at
1
site
St. Louis, Missouri 63108
?
mi
from
St. Louis, MO
Click here to add this to my saved trials